HIV p24 is the 230 amino acid phosphorylated protein of the capsid that forms the conical core of the virus that encapsulates the genomic complex of HIV. The ELISA Alliance HIV-1 p24 Antigen is for the detection of HIV-1 and HIV-0 subtypes in human serum, plasma, and cell culture supernatants. In gene therapy, HIV-derived lentiviral vectors are useful and commonly used to deliver transgenes to mammalian cells. Assays against the p24 antigen have become a standard method for measuring the efficacy of lentiviral transduction.
Here are some references that demonstrate that the p24 Alliance ELISA can be used for lentiviral transduction efficiency:
- Valkama, A., Leinonen, H., Lipponen, E., et al. Optimization of the production of lentiviral vectors for scaling in fixed-bed bioreactors. Gene Ther 25, 39-46 (2018).
- Majdoul S, Cosette J, Seye AK et al. Peptides derived from evolutionarily conserved domains in Beclin-1 and Beclin-2 enhance entry of lentiviral vectors into human cells. J Biol Chem. 2017; 292 (45): 18672-18681. DOI: 10.1074 / jbc.M117.800813
- Lesch, H., Laitinen, A., Peixoto, C., et al. Production and purification of lentiviral vectors generated in cells in suspension 293T with baculoviral vectors. Gene Ther 18, 531-538 (2011).
- Fenard D, Ingrao D, Seye A, et al. Vectofusin-1, a new viral entry enhancer, strongly promotes lentiviral transduction of human hematopoietic stem cells. Molecular therapy. Nucleic acids. 2013
- Ausubel LJ, Hall C, Sharma A, et al. Production of CGMP grade lentiviral vectors. Bioprocess Int. 2012; 10 (2): 32–43.
This kit provides reagents for immune complex disruption (ICD) of antigen/antibody complexes in serum and plasma samples and proprietary antibodies that increase the sensitivity of the assay. This kit is for research purposes only and is not approved for diagnostic use.